Carinoma of unknown primary site(CUP)
Conditions
Interventions
Nab-paclitaxel is administered as a 30-minute infusion at a dose of 100mg/m2 on days 1,8,and 15 followed by carboplatin at an AUC of5 mg.min/ml(per Calvert formula) given on day1, every 21 days. Respo
Sponsors
Teikyo University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with histologically comfirmed metastatic malignant lesion, with no identifiable primary site by physical examination, imaging, and laboratory examination. 2)No prior chemotherapy for CUP 3)Patients should be 20 years or older at informed consent. 4)ECOG PS scale: 0-2 5)Patient with enough feasibility for planned chemotherapy(hematological, liver, renal, cardiopulmonary function). 6)Written informed consent.
Exclusion criteria
Exclusion criteria: 1)Indication for radical operation and radiotherapy. 2)Patients unable to take nab-paclitaxel and CBDCA because of significant cardiovascular abnormalities, renal dysfunctions, hepatic insufficiency, uncontrolled diabetes, uncontrolled hypertension, bleeding tendency, active interstitial pneumonia,etc. 3)Known active brain metastasis. 4)Acute or subacute idiopathic interstitial pneumonia 5)Patient received a bone-marrow transplantation 6)Patient received a peripheral stem cell transplantation 7)Known hypersensitivity to any drugs 8)Seropositivity for HBsAg 9)Pregnancy or breast feeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival, overall survival,response rate,tumor control rate,adverse event,QOL | — |
Countries
Japan
Contacts
Public ContactYasuko Ichikawa
Teikyo University School of Medicine Division of Medical Oncology,Department of Internal Mediine
Outcome results
None listed